C12N2770/24132

Compositions and methods for combination therapy with dengue virus and dendritic cells
10946080 · 2021-03-16 · ·

Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.

COMPOSITIONS AND METHODS FOR PRODUCING DENDRITIC CELLS
20200360497 · 2020-11-19 ·

Described herein are compositions and methods for treating a disease, particularly a cancer, with primed dendritic cells recognizing a tumor antigen. The methods may comprise storing, shipping and/or culturing dendritic cells, where the dendritic cells are stored on a hard surface. Lysis protocols are described where the lysis does not result in complete lysis of cells in order to provide cell surface molecules maintained in a cell surface-embedded state. Non-lethal Dengue virus strains are also provided for therapeutic purposes.

ONCOLYTIC CANCER IMMUNOTHERAPIES AND METHODS OF USE
20200330581 · 2020-10-22 ·

Disclosed herein are methods of treating a brain cancer comprising administering to a subject in need thereof a viral composition comprising a flavivirus or portion of a flavivirus wherein the flavivirus is engineered to comprise a heterologous nucleic acid sequence encoding a suicide gene. In some embodiments, the brain cancer is selected from the group consisting of astrocytoma, oligodendroglioma, ependymoma, meningioma, schwannoma, craniopharyngioma, germinoma, and pineocytoma. In some embodiments the flavivirus comprises Zika virus, spondweni virus, kedougous virus, or a combination thereof. In some embodiments, the flavivirus comprises Zika virus. In some embodiments, the suicide gene encodes a protein that converts a prodrug into a cytotoxic agent. In some embodiments, the viral composition is administered in combination with the immunostimulatory agent.

TUMOR ORGANOID MODEL
20200308550 · 2020-10-01 ·

A method of generating an artificial 3D tissue culture of a cancer grown in non-cancerous tissue, includes the steps of providing an aggregate of pluripotent stem cells or progenitor cells, culturing and expanding the cells in a 3D biocompatible matrix, wherein the cells are allowed to differentiate to develop the aggregate into a tissue culture of a desired size; wherein at least a portion of the cells are subjected to cancerogenesis by expressing a oncogene and/or by suppressing a tumor suppressor gene during any of the steps or in the tissue culture, and further including the step of allowing the cells with an expressed oncogene or suppressed tumor suppressor to develop into cancerous cells; drug screening methods; oncolytic virus screening methods; a 3D tissue culture; and a kit for performing the inventive methods.

Compositions and methods for producing dendritic cells

Described herein are compositions and methods for treating a disease, particularly a cancer, with primed dendritic cells recognizing a tumor antigen. The methods may comprise storing, shipping and/or culturing dendritic cells, where the dendritic cells are stored on a hard surface. Lysis protocols are described where the lysis does not result in complete lysis of cells in order to provide cell surface molecules maintained in a cell surface-embedded state. Non-lethal Dengue virus strains are also provided for therapeutic purposes.

Compositions and Methods for Antigen Targeting to CD180
20200216819 · 2020-07-09 ·

The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.

COMBINATION OF IMMUNO-ONCOLYTIC VIRUS DRUGS FOR ENHANCING SYSTEMIC IMMUNE RESPONSE AND APPLICATION THEREOF
20200215133 · 2020-07-09 ·

This disclosure provides the innovation of a group of flaviviruses carrying respective lymphocyte genes that results in targeting specific T cells of immune system to therapy solid cancers and provides strategies for using these oncolytic viruses to reduce or to avoid immune resistance to single virus treatment and thus increase efficiency against cancer.

COMPOSITIONS AND METHODS FOR THERAPY WITH DENGUE VIRUS
20200078424 · 2020-03-12 ·

Described herein are compositions and methods for treating a disease, particularly a cancer, with a Dengue Virus and, optionally, primed dendritic cells recognizing a tumor antigen. Lysis protocols are described where the lysis does not result in complete or less than complete lysis of cells in order to provide cell surface molecules maintained in a cell surface-embedded state. Non-lethal Dengue virus strains are also provided for therapeutic purposes.

COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS
20190247479 · 2019-08-15 ·

Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.

Compositions and methods for combination therapy with dengue virus and dendritic cells
10357553 · 2019-07-23 · ·

Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.